Entrada Therapeutics 8-K Filing: Corporate Office Update

Ticker: TRDA · Form: 8-K · Filed: Jan 15, 2025 · CIK: 1689375

Entrada Therapeutics, Inc. 8-K Filing Summary
FieldDetail
CompanyEntrada Therapeutics, Inc. (TRDA)
Form Type8-K
Filed DateJan 15, 2025
Risk Levellow
Pages3
Reading Time4 min
Key Dollar Amounts$0.0001, $420.0 million
Sentimentneutral

Sentiment: neutral

Topics: corporate-filing, address-change

Related Tickers: TRDA

TL;DR

TRDA updated its corporate address in Boston, MA.

AI Summary

On January 15, 2025, Entrada Therapeutics, Inc. (TRDA) filed an 8-K report. The filing indicates the company's principal executive offices are located at One Design Center Place, Suite 17-500, Boston, MA 02210. The report confirms that the company's common stock trades on The Nasdaq Global Market under the symbol TRDA.

Why It Matters

This filing provides an update on the company's official address, which is important for regulatory compliance and investor awareness of its operational base.

Risk Assessment

Risk Level: low — This is a routine administrative filing updating the company's address and does not involve significant financial or operational changes.

Key Players & Entities

  • Entrada Therapeutics, Inc. (company) — Registrant
  • TRDA (company) — Trading Symbol
  • The Nasdaq Global Market (company) — Exchange
  • One Design Center Place, Suite 17-500, Boston, MA 02210 (location) — Principal executive offices

FAQ

What is the primary purpose of this 8-K filing?

The primary purpose of this 8-K filing is to report current information as required by the SEC, specifically updating the registrant's principal executive offices.

What is the trading symbol for Entrada Therapeutics, Inc. common stock?

The trading symbol for Entrada Therapeutics, Inc. common stock is TRDA.

On which exchange is Entrada Therapeutics, Inc. common stock traded?

Entrada Therapeutics, Inc. common stock is traded on The Nasdaq Global Market.

What is the new address for Entrada Therapeutics, Inc.'s principal executive offices?

The new address for Entrada Therapeutics, Inc.'s principal executive offices is One Design Center Place, Suite 17-500, Boston, MA 02210.

Is Entrada Therapeutics, Inc. considered an emerging growth company?

Yes, Entrada Therapeutics, Inc. has indicated by check mark that it is an emerging growth company.

Filing Stats: 972 words · 4 min read · ~3 pages · Grade level 12.1 · Accepted 2025-01-15 16:05:40

Key Financial Figures

  • $0.0001 — ge on which registered Common Stock, $0.0001 par value per share TRDA The Nasdaq
  • $420.0 million — rketable securities, were approximately $420.0 million as of December 31, 2024 and that it exp

Filing Documents

02 Results of Operations and Financial Condition

Item 2.02 Results of Operations and Financial Condition. On January 15, 2025, Entrada Therapeutics, Inc. (the "Company") presented at the 43 rd Annual J.P. Morgan Healthcare Conference, which presentation included certain preliminary financial results as of and for the fiscal year ended December 31, 2024. Specifically, the Company announced that its cash resources, which consist of cash, cash equivalents and marketable securities, were approximately $420.0 million as of December 31, 2024 and that it expects such cash resources to fund operations and capital expenditure requirements into the second quarter of 2027. The information in this Item 2.02 is unaudited and preliminary, and it does not present all information necessary for an understanding of the Company's results of operations for the fiscal year ended December 31, 2024, or financial condition as of December 31, 2024. The audit of the Company's financial statements for the year ended December 31, 2024 is ongoing and could result in changes to the information in this Item 2.02. The information in Item 2.02 of this Current Report on Form 8-K is intended to be furnished and shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing.

01 Other Events

Item 8.01 Other Events. A copy of the Company's presentation for use by management in meetings with investors, analysts and others during the 43 rd Annual J.P. Morgan Healthcare Conference is attached as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.

Forward Looking Statements

Forward Looking Statements This Current Report on Form 8-K includes express and implied "forward-looking statements." Forward looking statements include all statements that are not historical facts, and in some cases, can be identified by terms such as "may," "might," "will," "could," "would," "should," "expect," "intend," "plan," "objective," "anticipate," "believe," "estimate," "predict," "potential," "continue," "ongoing," or the negative of these terms, or other comparable terminology intended to identify statements about the future. Forward-looking statements contained in this Current Report on Form 8-K include, but are not limited to, statements about the Company's preliminary and unaudited estimate of cash resources and the sufficiency of its cash resources through the second quarter of 2027. By their nature, these results, performance or achievement to differ materially and adversely from those anticipated or implied in the statements. For further information regarding the risks, uncertainties and other factors that may cause differences between the Company's expectations and actual results, you should review the "Risk Factors" in Item 1A of Part II of the Company's Quarterly Report on Form 10-Q for the quarter ended September 30, 2024, as well as discussions of potential risks, uncertainties and other important factors in the Company's subsequent filings. You should not rely upon forward-looking statements as predictions of future events. Although the Company's management believes that the expectations reflected in the Company's statements are reasonable, the Company cannot guarantee that the future results, performance or events and circumstances described in the forward-looking statements will be achieved or occur. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the

01 Financial Statements and Exhibits

Item 9.01 Financial Statements and Exhibits. (d) Exhibits. 99.1 Corporate Presentation of Entrada Therapeutics, Inc. as of January 15, 2025. 104 Cover Page Interactive Data File (embedded within the Inline XBRL document). SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Entrada Therapeutics, Inc. Date: January 15, 2025 By: /s/ Dipal Doshi Dipal Doshi Chief Executive Officer

View Full Filing

View this 8-K filing on SEC EDGAR

View on ReadTheFiling | About | Contact | Privacy | Terms

Data from SEC EDGAR. Not affiliated with the SEC. Not investment advice. © 2026 OpenDataHQ.